Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study | Zendy

Maya LeventerRoberts | Zendy; Becca Feldman | Zendy; Ilan Brufman | Zendy; Chandra J. Cohen-Stavi | Zendy; Moshe Hoshen | Zendy; Ran D. Balicer | Zendy

Open Access

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study

Author(s) -

Maya LeventerRoberts,

Becca Feldman,

Ilan Brufman,

Chandra J. Cohen-Stavi,

Moshe Hoshen,

Ran D. Balicer

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ096

Subject(s) - medicine , pneumococcal disease , pneumonia , retrospective cohort study , pneumococcal polysaccharide vaccine , streptococcus pneumoniae , pneumococcal pneumonia , pneumococcal vaccine , intensive care medicine , pneumococcal infections , pediatrics , immunology , microbiology and biotechnology , antibiotics , biology

Streptococcus pneumoniae contributes considerably to the burden of pneumonia and invasive pneumococcal disease (IPD), with the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for preventing all-cause pneumonia still undetermined. The aim of this study was to control for common biases and confounders associated with previous observational studies and to assess PPSV23 vaccine effectiveness in preventing IPD and the most resource-intensive type of community-acquired pneumonia, hospital-treated pneumonia (HTP).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research